Garamycin® Ophthalmic Solution Now Available from Fera Pharmaceuticals

NEW YORK--(BUSINESS WIRE)-- Fera Pharmaceuticals announced the launch today of Garamycin (gentamicin sulfate) Ophthalmic Solution USP.

Garamycin Ophthalmic Solution, a broad spectrum anti-infective, is indicated for the treatment of ocular bacterial infections such as conjunctivitis, keratitis and blepharitis.

Garamycin is a trusted brand name and the product is a favorite among physicians who are looking for a single ingredient anti-infective ophthalmic solution.

About Fera Pharmaceuticals, LLC

Fera Pharmaceuticals is a privately held company. The company goal is to realize opportunities via acquisitions, in-licensing, developing and marketing abbreviated new drug applications (ANDAs), new drug applications (NDAs) and 505(b)(2) NDA products. For more information visit www.ferapharma.com.

Garamycin is a registered trademark of Fera Pharmaceuticals.



CONTACT:

Fera Pharmaceuticals, LLC
Susan McDougal, 516-277-1450
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Hospitals  Infectious Diseases  Optical  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.